Clinical Study
De Novo Donor-Specific HLA Antibody Development and Peripheral Cells in Kidney Transplant Recipients: A Place for Interaction?
Table 2
Acute rejection episodes.
| | DSA−
N = 36 | DSA+
N = 17 |
| Number (%) of patients with acute
rejection episodes | 2 (5.6) | 6 (35.3)* | | Number of acute rejection episodes | 3 | 9 | | Banff 97 grade and the 03 update working classification | | | | Acute/active cellular rejection | | | | Mild acute (IA) | 1 | 1 | | Mild acute (IB) | 0 | 3 | | Moderate acute (IIA) | 1 | 1 | | Moderate acute (IIB) | 0 | 0 | | Severe acute (III) | 0 | 1 | | Antibody-mediated rejection | | | | I | 0 | 0 | | II | 1 | 2 | | III | 0 | 1 |
|
|
(Fisher exact test).
|
